#1 Clinical Trials Search in Europe

Human Papillomavirus Type 11 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

This article summarizes several clinical trials investigating the use of the 9-valent human papillomavirus (HPV) vaccine, also known as Gardasil 9, for preventing and treating various HPV-related conditions. The trials examine the vaccine’s efficacy, safety, and immunogenicity in different populations and clinical scenarios, including extended dosing schedules, immunocompromised patients, and treatment of HPV-related lesions. These studies aim to optimize the use of the HPV vaccine and explore its potential therapeutic applications beyond standard preventive vaccination.

Table of Contents

What is the HPV Vaccine?

The HPV vaccine discussed in these clinical trials is a 9-valent human papillomavirus (HPV) vaccine that protects against 9 types of HPV, including type 11[1]. It is also known by the brand name Gardasil 9. The vaccine contains virus-like particles that mimic HPV, produced using recombinant DNA technology in yeast cells[1].

This vaccine is designed to prevent HPV infections and HPV-related diseases, including:

  • Cervical, vulvar, vaginal, and anal cancers
  • Precancerous lesions
  • Genital warts
  • Persistent HPV infections

How Does the HPV Vaccine Work?

The vaccine works by stimulating the body’s immune system to produce antibodies against specific HPV types. When a person is later exposed to these HPV types, the antibodies can help prevent infection[1]. The vaccine targets the L1 protein of HPV, which is a major component of the virus’s outer shell.

For HPV type 11 specifically, the vaccine contains:

HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN – ADSORBED – IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA

This means the vaccine uses harmless virus-like particles that resemble HPV type 11, created using genetic engineering techniques in yeast cells[1].

Who Should Get the HPV Vaccine?

Based on the clinical trials, the HPV vaccine is being studied in various age groups and populations:

  • Children and adolescents aged 9-14 years[1]
  • Young adults aged 16-26 years[1]
  • Adult males aged 20-45 years[2]
  • Women over 45 years who have been treated for high-grade cervical lesions[3]
  • Immunocompromised children and adolescents[4]

The vaccine is most effective when given before exposure to HPV, which is why it is recommended for younger age groups. However, research is ongoing to determine its benefits in other populations.

Dosing Schedule

The typical dosing schedule for the HPV vaccine is:

  • 3 doses given over 6 months[1]
  • Some studies are investigating 2-dose schedules with extended intervals between doses for younger age groups[1]

The vaccine is administered as an intramuscular injection, usually in the upper arm or thigh[1].

Effectiveness

Clinical trials are evaluating the effectiveness of the HPV vaccine in various ways:

  • Measuring antibody responses to each HPV type[1]
  • Assessing prevention of persistent HPV infections[2]
  • Evaluating reduction in recurrence of cervical lesions after treatment[3]
  • Investigating its impact on difficult-to-treat warts[5]

Early results suggest the vaccine is highly effective in preventing HPV infections and related diseases when given before exposure to the virus.

Safety and Side Effects

The HPV vaccine has been extensively tested and is considered safe. Common side effects may include:

  • Pain, redness, or swelling at the injection site
  • Fever
  • Headache
  • Nausea

Serious side effects are rare. The clinical trials are closely monitoring for any adverse events to ensure the vaccine’s safety profile[1][2].

Ongoing Research

Current clinical trials are investigating:

  • Extended dosing intervals in younger age groups[1]
  • Effectiveness in preventing oral HPV infections in adult males[2]
  • Use as adjuvant therapy after treatment for cervical lesions[3]
  • Efficacy in immunocompromised populations[4]
  • Potential for treating difficult warts[5]

These studies aim to expand our understanding of the vaccine’s benefits and optimize its use in different populations.

Trial Focus Population Key Objectives Main Endpoints
Extended dosing intervals Children and adolescents 9-14 years old Evaluate safety and immunogenicity of 2-dose regimens with extended intervals Antibody levels, seroconversion rates, safety profile
Immunocompromised patients Immunocompromised children and adolescents Assess immunogenicity in various immunocompromised groups Seroconversion rates, antibody levels, immune response markers
Oral HPV prevention Adult males 20-45 years old Evaluate efficacy in preventing oral HPV infections Incidence of oral HPV persistent infections, antibody responses
Vulvar HSIL treatment Women with vulvar HSIL Assess efficacy of adjuvant vaccination in preventing recurrence Recurrence rates, immune responses, quality of life
Post-LEEP vaccination Women treated for high-grade cervical lesions Evaluate impact on disease recurrence and HPV clearance Recurrence rates, persistent HPV infection rates, follow-up times
Palmar/plantar warts Patients with difficult-to-treat warts Assess efficacy in treating recalcitrant warts Complete remission rates, quality of life, pain reduction

FAQ

  • What is the 9-valent HPV vaccine? The 9-valent HPV vaccine, also known as Gardasil 9, is a vaccine that protects against nine types of human papillomavirus (HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58). It is designed to prevent HPV-related diseases such as cervical, vulvar, vaginal, and anal cancers, as well as genital warts.
  • What populations are being studied in these clinical trials? The clinical trials are studying various populations, including children and adolescents aged 9-14 years, adult males aged 20-45 years, immunocompromised children and adolescents, women with high-grade cervical lesions or early cervical cancer, and patients with difficult-to-treat palmar or plantar warts.
  • What are some of the main objectives of these clinical trials? The main objectives of these trials include evaluating the safety and immunogenicity of extended dosing schedules, assessing the vaccine's efficacy in preventing oral HPV infections in adult males, studying its effectiveness in immunocompromised patients, and investigating its potential therapeutic effects in treating HPV-related lesions and preventing disease recurrence.
  • How is the vaccine administered in these trials? The vaccine is typically administered as an intramuscular injection. The dosing schedules vary between trials, with some studies investigating extended interval dosing (e.g., 2 doses given 12-60 months apart) and others following the standard 3-dose regimen (0, 2, and 6 months).
  • What are some potential benefits being investigated in these trials? The trials are investigating potential benefits such as improved immune responses with extended dosing intervals, prevention of oral HPV infections in adult males, reduction of disease recurrence in patients treated for cervical or vulvar lesions, and possible therapeutic effects on difficult-to-treat warts. Some studies also aim to optimize follow-up schedules and reduce the burden of post-treatment surveillance.

Ongoing Clinical Trials on Human Papillomavirus Type 11 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

Glossary

  • HPV (Human Papillomavirus): A group of viruses that can cause various types of cancer and genital warts. There are many types of HPV, some of which are targeted by the 9-valent vaccine.
  • 9vHPV vaccine: The 9-valent HPV vaccine, also known as Gardasil 9, which protects against nine types of HPV (6, 11, 16, 18, 31, 33, 45, 52, and 58).
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent, indicating an immune response to vaccination or infection.
  • LEEP (Loop Electrosurgical Excision Procedure): A procedure used to remove abnormal tissue from the cervix using a thin wire loop heated by electric current.
  • CIN (Cervical Intraepithelial Neoplasia): Abnormal changes in the cells on the surface of the cervix that may progress to cervical cancer if left untreated.
  • HSIL (High-grade Squamous Intraepithelial Lesion): A precancerous condition characterized by abnormal cell changes in the cervix or other areas, which may progress to cancer if not treated.
  • Conization: A surgical procedure to remove a cone-shaped piece of tissue from the cervix for diagnostic or treatment purposes.
  • Colposcopy: A procedure that uses a special magnifying device (colposcope) to examine the cervix, vagina, and vulva for signs of disease.
  • HPV clearance: The elimination of HPV infection from the body, typically through the immune system's response.
  • Geometric Mean Titers (GMT): A measure of the average antibody levels in a group of individuals, used to assess the immune response to a vaccine.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare with the effects of the investigational drug or vaccine.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  3. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-after-treatment-for-high-grade-cervical-lesions-in-women-over-45/
  4. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  5. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-the-nonavalent-hpv-vaccine-in-treating-hard-to-treat-palmar-or-plantar-warts-in-patients-who-have-not-responded-to-two-previous-treatments/